🇺🇸 FDA
Patent

US 10093676

Compounds useful as inhibitors of ATR kinase

granted A61PA61P35/00A61P43/00

Quick answer

US patent 10093676 (Compounds useful as inhibitors of ATR kinase) held by Vertex Pharmaceuticals Incorporated expires Mon Oct 04 2038 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
Vertex Pharmaceuticals Incorporated
Grant date
Tue Oct 09 2018 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Oct 04 2038 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
19
CPC classes
A61P, A61P35/00, A61P43/00